Search - tctmd.com

Displaying 81 - 100 of 135

Sort: Relevancy | Date

Presentation TCT 2014

Edoxaban in ACS and Atrial Fibrillation: Risk/Benefit Analysis and Future Directions

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Michael D. Ezekowitz

September 15, 2014

Presentation TCT 2014

Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Christopher B. Granger

September 15, 2014

Presentation TCT 2014

Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson

September 15, 2014

Presentation TCT 2014

Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Laura Mauri

September 15, 2014

Presentation TCT 2014

Comparative Analysis of Warfarin and the NOACs: Differentiating Properties, Risks, and Benefits

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Jonathan L. Halperin

September 15, 2014

Presentation TCT 2014

The REG1 Anticoagulation System: Factor IX Inhibitor Using RNA Aptamer Technology

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, A. Michael Lincoff

September 15, 2014

Presentation TCT 2014

Old and New Anticoagulants for Stroke Prevention: Benefits and Risks

Presenter: Josep Rodés-Cabau, Brian K. Whisenant, David Hildick-Smith, Jonathan L. Halperin

September 15, 2014

Presentation TCT 2014

Putting it All Together: Anticoagulants, Rhythm Control, and LAA Closure Which Therapy for Which Patient?

Presenter: Matthew J. Price, Shephal Doshi

September 15, 2014

Presentation TCT 2014

ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation

Presenter: Roxana Mehran, Harvey D. White, Nikolaus Sarafoff

September 15, 2014

Presentation TCT 2014

Atrial Fibrillation: Stratifying Stroke Risk and Determining Anticoagulant Therapy

Presenter: Hilary Nierenberg, Julie Logan, Asma Hussaini

September 14, 2014

Presentation TCT 2014

Position Statement: Heparin Will Once Again Become the Anticoagulant of Choice for PCI in Stable and Unstable Coronary Syndromes

Presenter: Kishore J. Harjai, Michael S. Lee

September 14, 2014

Presentation TCT 2014

Role of New Oral Anticoagulants and New ADP Antagonists in ACS Patients

Presenter: Roxana Mehran, Mohamed Sobhy

September 13, 2014

Presentation LAA 2014

Watchman: Randomized Trial Data in Anticoagulant Eligible Patients(from PROTECT AF to CAP to PREVAIL)

Presenter: David R. Holmes

July 19, 2014

Presentation LAA 2014

Watchman: Non-Randomized Trial Data in Anticoagulant Ineligible Patients ASAP and more

Presenter: Vivek Y. Reddy

July 19, 2014

Presentation LAA 2014

Outcomes Data with the Amplatzer Cardiac Plug in Anticoagulant Eligible and Ineligible Patients

Presenter: Josep Rod?s-Cabau

July 19, 2014

Presentation LAA 2014

Novel Anticoagulants

Presenter: Michael D. Ezekowitz

July 17, 2014

Presentation

Anticoagulant and Antiplatelet Therapy in A-fib Patients Undergoing PCI

Presenter: K. Goto

April 30, 2014

Presentation Fellows 2014

Navigating the New Oral Anticoagulants and Triple Therapy

Presenter: George D. Dangas

April 13, 2014

Presentation Fellows 2014

Navigating the New Oral Anticoagulants and How to Deal with Triple Therapy

Presenter: George Dangas

April 12, 2014

Presentation

The Quality of Antiplatelet and Anticoagulant Medication Administration Among STEMI Patients Transferred for Primary PCI

Presenter: Tracy Y. Wang

March 27, 2014

Advertisement

Edoxaban in ACS and Atrial Fibrillation: Risk/Benefit Analysis and Future Directions

Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin

Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts

Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial

Comparative Analysis of Warfarin and the NOACs: Differentiating Properties, Risks, and Benefits

The REG1 Anticoagulation System: Factor IX Inhibitor Using RNA Aptamer Technology

Old and New Anticoagulants for Stroke Prevention: Benefits and Risks

Putting it All Together: Anticoagulants, Rhythm Control, and LAA Closure Which Therapy for Which Patient?

ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation

Atrial Fibrillation: Stratifying Stroke Risk and Determining Anticoagulant Therapy

Position Statement: Heparin Will Once Again Become the Anticoagulant of Choice for PCI in Stable and Unstable Coronary Syndromes

Role of New Oral Anticoagulants and New ADP Antagonists in ACS Patients

Watchman: Randomized Trial Data in Anticoagulant Eligible Patients(from PROTECT AF to CAP to PREVAIL)

Watchman: Non-Randomized Trial Data in Anticoagulant Ineligible Patients ASAP and more

Outcomes Data with the Amplatzer Cardiac Plug in Anticoagulant Eligible and Ineligible Patients

Novel Anticoagulants

Anticoagulant and Antiplatelet Therapy in A-fib Patients Undergoing PCI

Navigating the New Oral Anticoagulants and Triple Therapy

Navigating the New Oral Anticoagulants and How to Deal with Triple Therapy

The Quality of Antiplatelet and Anticoagulant Medication Administration Among STEMI Patients Transferred for Primary PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content